Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2014 (2014), Article ID 921863, 16 pages
http://dx.doi.org/10.1155/2014/921863
Research Article

Chemical Feature-Based Molecular Modeling of Urotensin-II Receptor Antagonists: Generation of Predictive Pharmacophore Model for Early Drug Discovery

1Department of Pharmacy, Banasthali University, Rajasthan 304022, India
2Department of Pharmacy, LLRM Medical College, Meerut, Uttar Pradesh 250004, India

Received 6 May 2013; Revised 19 November 2013; Accepted 3 December 2013; Published 3 February 2014

Academic Editor: Georgia Melagraki

Copyright © 2014 Anubhuti Pandey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. S. Ames, H. M. Sarau, J. K. Chambers et al., “Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14,” Nature, vol. 401, no. 6750, pp. 282–286, 1999. View at Google Scholar
  2. C. D. Proulx, B. J. Holleran, P. Lavigne, E. Escher, G. Guillemette, and R. Leduc, “Biological properties and functional determinants of the urotensin II receptor,” Peptides, vol. 29, no. 5, pp. 691–699, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. B. E. Maryanoff and W. A. Kinney, “Urotensin-II receptor modulators as potential drugs,” Journal of Medicinal Chemistry, vol. 53, no. 7, pp. 2695–2708, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Clozel, P. Hess, C. Qiu, S.-S. Ding, and M. Rey, “The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 3, pp. 1115–1121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. “Actelion provides update on palosuran in diabetic nephropathy,” http://www1.actelion.com/en/our-company/news-and-events/index.page?newsId=1209557.
  6. P. J. Lakshmi, B. V. S. Kumar, R. S. Nayana et al., “Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach,” Bioorganic and Medicinal Chemistry, vol. 17, no. 16, pp. 6040–6047, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Sundriyal, R. K. Sharma, R. Jain, and P. V. Bharatam, “Minimum requirements of hydrophobic and hydrophilic features in cationic peptide antibiotics (CPAs): pharmacophore generation and validation with cationic steroid antibiotics (CSAs),” Journal of Molecular Modeling, vol. 14, no. 4, pp. 265–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Paliwal, M. Pal, D. Yadav, S. Singh, and R. Yadav, “Ligand-based drug design studies using predictive pharmacophore model generation on 4H-1,2,4-triazoles as AT1 receptor antagonists,” Medicinal Chemistry Research, vol. 21, no. 9, pp. 2307–2315, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Lu, F. Jin, C. Li, W. Li, G. Liu, and Y. Tang, “Insights into binding modes of 5-HT2c receptor antagonists with ligand-based and receptor-based methods,” Journal of Molecular Modeling, vol. 17, no. 10, pp. 2513–2523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. K. K. Roy, S. Singh, and A. K. Saxena, “Integration-mediated prediction enrichment of Quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study,” Molecular Diversity, vol. 15, no. 2, pp. 477–489, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Yadav, S. Paliwal, R. Yadav, M. Pal, and A. Pandey, “Identification of novel HIV 1-protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening,” PLoS ONE, vol. 7, no. 11, Article ID e48942, 2012. View at Publisher · View at Google Scholar
  12. E. Lescot, J. S. O. Santos, C. Dubessy et al., “Definition of new pharmacophores for nonpeptide antagonists of human urotensin-II. Comparison with the 3D-structure of human urotensin-II and URP,” Journal of Chemical Information and Modeling, vol. 47, no. 2, pp. 602–612, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Lescot, J. S. O. Santos, N. Colloc'h et al., “Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model,” Proteins, vol. 73, no. 1, pp. 173–184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. E. C. Lawson, D. K. Luci, S. Ghosh et al., “Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits,” Journal of Medicinal Chemistry, vol. 52, no. 23, pp. 7432–7445, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Langer and R. D. Hoffmann, “Pharmacophore model generation software tools,” in Pharmacophores and Pharmacophores Searches, Methods and Principles in Medicinal Chemistry, pp. 17–44, Wiley-VCH, Weinheim, Germany, 2006. View at Google Scholar
  16. K. S. Watts, P. Dalal, R. B. Murphy, W. Sherman, R. A. Friesner, and J. C. Shelley, “ConfGen: a conformational search method for efficient generation of bioactive conformers,” Journal of Chemical Information and Modeling, vol. 50, no. 4, pp. 534–546, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Smellie, S. L. Teig, and P. Towbin, “Poling: promoting conformational variation,” Journal of Computational Chemistry, vol. 16, no. 2, pp. 171–187, 1995. View at Publisher · View at Google Scholar
  18. M. Tonelli, V. Boido, P. L. Colla et al., “Pharmacophore modeling, resistant mutant isolation, docking, and MM-PBSA analysis: combined experimental/computer-assisted approaches to identify new inhibitors of the bovine viral diarrhea virus (BVDV),” Bioorganic and Medicinal Chemistry, vol. 18, no. 6, pp. 2304–2316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. D. K. Luci, S. Ghosh, C. E. Smith et al., “Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 23, pp. 6489–6492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Bousette, F. Hu, E. H. Ohlstein, D. Dhanak, S. A. Douglas, and A. Giaid, “Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation,” Journal of Molecular and Cellular Cardiology, vol. 41, no. 2, pp. 285–295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. S. A. Douglas, D. J. Behm, N. V. Aiyar et al., “Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375,” The British Journal of Pharmacology, vol. 145, no. 5, pp. 620–635, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Jin, D. Dhanak, S. D. Knight et al., “Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 13, pp. 3229–3232, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Jin, M. An, A. Sapienza et al., “Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 14, pp. 3950–3954, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. C. A. Lipinski, “Drug-like properties and the causes of poor solubility and poor permeability,” Journal of Pharmacological and Toxicological Methods, vol. 44, no. 1, pp. 235–249, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. I. Muegge, “Selection criteria for drug-like compounds,” Medicinal Research Reviews, vol. 23, no. 3, pp. 302–321, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. O. F. Güner, “HypoGen: an automated system for generating 3D predictive pharmacophore models,” in Pharmacophore Perception, Development, and Use in Drug Design, IUL Biotechnology Series, pp. 171–189, International University Line, La Jolla, Calif, USA, 2000. View at Google Scholar
  27. M. Pal and S. Paliwal, “In silico identification of novel lead compounds with AT1 receptor antagonist activity: successful application of chemical database screening protocol,” Organic and Medicinal Chemistry Letters, vol. 2, no. 1, article 7, 2012. View at Publisher · View at Google Scholar